> top > docs > PubMed:27063942 > annotations

PubMed:27063942 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 14-25 CHEBI:67194 denotes cannabinoid
T2 26-29 P47936 denotes CB2
T3 26-29 P34972 denotes CB2
T4 26-29 P24027 denotes CB2
T5 26-29 PR:000001126 denotes CB2
T6 26-29 Q9QZN9 denotes CB2
T7 26-38 D043885 denotes CB2 receptor
T8 89-94 PR:Q5S006 denotes LRRK2
T9 89-94 PR:000003033 denotes LRRK2
T10 89-94 PR:Q5S007 denotes LRRK2
T11 95-105 SO:0000781 denotes transgenic
T12 95-110 10090 denotes transgenic mice
T13 95-110 D008822 denotes transgenic mice
T14 106-110 PR:000005054 denotes mice
T16 106-110 O89094 denotes mice
T22 129-148 D010300 denotes Parkinson's disease
T23 129-148 D010300 denotes Parkinson's disease
T26 203-210 32644 denotes unknown
T27 318-330 D020734 denotes parkinsonism
T28 318-330 D020734 denotes parkinsonism
T30 412-421 P37379 denotes synuclein
T29 412-421 D051843 denotes synuclein
T31 423-429 O60260 denotes parkin
T33 450-457 6308 denotes leucine
T34 450-457 SO:0001437 denotes leucine
T32 450-457 CHEBI:15603 denotes leucine
T35 450-457 D007930 denotes leucine
T36 450-457 CHEBI:25017 denotes leucine
T37 450-457 D007930 denotes leucine
T38 463-469 SO:0001068 denotes repeat
T39 480-485 PR:Q5S006 denotes LRRK2
T40 480-485 PR:000003033 denotes LRRK2
T41 480-485 PR:Q5S007 denotes LRRK2
T42 501-509 SO:0000109 denotes mutation
T43 548-558 D000067562 denotes late-onset
T44 548-558 D000067562 denotes late-onset
T45 560-578 C566739 denotes autosomal dominant
T46 594-604 SO:0000781 denotes transgenic
T47 594-610 D008822 denotes transgenic mouse
T50 639-647 SO:0000109 denotes mutation
T51 651-656 PR:Q5S006 denotes LRRK2
T52 651-656 PR:000003033 denotes LRRK2
T53 651-656 PR:Q5S007 denotes LRRK2
T54 758-770 GO:0009405 denotes pathogenesis
T55 812-816 original_id denotes term
T56 899-914 D063388 denotes endocannabinoid
T57 899-914 CHEBI:67197 denotes endocannabinoid
T58 899-914 D063388 denotes endocannabinoid
T59 915-924 GO:0023052 denotes signaling
T60 939-952 UBERON:0002420 denotes basal ganglia
T63 939-952 UBERON:0006098 denotes basal ganglia
T64 939-952 UBERON:0010011 denotes basal ganglia
T61 939-952 D001480 denotes basal ganglia
T62 939-952 D001480 denotes basal ganglia
T66 983-990 D004194 denotes disease
T67 983-990 D004194 denotes disease
T69 1000-1004 D051379 denotes mice
T71 1000-1004 10095 denotes mice
T68 1000-1004 PR:000005054 denotes mice
T70 1000-1004 O89094 denotes mice
T72 1029-1032 P47936 denotes CB2
T73 1029-1032 P34972 denotes CB2
T74 1029-1032 P24027 denotes CB2
T75 1029-1032 PR:000001126 denotes CB2
T76 1029-1032 Q9QZN9 denotes CB2
T77 1029-1041 D043885 denotes CB2 receptor
T78 1165-1168 P47936 denotes CB2
T79 1165-1168 P34972 denotes CB2
T80 1165-1168 P24027 denotes CB2
T81 1165-1168 PR:000001126 denotes CB2
T82 1165-1168 Q9QZN9 denotes CB2
T83 1165-1177 D043885 denotes CB2 receptor
T84 1182-1189 D004194 denotes disease
T85 1182-1189 D004194 denotes disease
T87 1216-1220 D051379 denotes mice
T89 1216-1220 10095 denotes mice
T86 1216-1220 PR:000005054 denotes mice
T88 1216-1220 O89094 denotes mice
T90 1265-1270 PR:Q5S006 denotes LRRK2
T91 1265-1270 PR:000003033 denotes LRRK2
T92 1265-1270 PR:Q5S007 denotes LRRK2
T93 1271-1281 SO:0000781 denotes transgenic
T94 1271-1286 10090 denotes transgenic mice
T95 1271-1286 D008822 denotes transgenic mice
T96 1282-1286 PR:000005054 denotes mice
T98 1282-1286 O89094 denotes mice
T100 1407-1419 MOP:0000797 denotes coordination
T101 1424-1432 D004421 denotes dystonia
T102 1424-1432 D004421 denotes dystonia
T103 1447-1457 SO:1000029 denotes deficiency
T104 1495-1501 UBERON:0001630 denotes muscle
T105 1495-1501 UBERON:0005090 denotes muscle
T106 1495-1510 D018908 denotes muscle weakness
T107 1495-1510 D018908 denotes muscle weakness
T108 1525-1536 D018476 denotes hypokinesia
T109 1525-1536 D018476 denotes hypokinesia
T110 1660-1676 GO:0150103 denotes reactive gliosis
T112 1669-1676 D005911 denotes gliosis
T113 1669-1676 D005911 denotes gliosis
T114 1739-1752 UBERON:0002420 denotes basal ganglia
T117 1739-1752 UBERON:0006098 denotes basal ganglia
T118 1739-1752 UBERON:0010011 denotes basal ganglia
T115 1739-1752 D001480 denotes basal ganglia
T116 1739-1752 D001480 denotes basal ganglia
T120 1787-1796 GO:0016236 denotes autophagy
T121 1787-1796 GO:0006914 denotes autophagy
T124 1819-1825 PR:P14562 denotes LAMP-1
T125 1819-1825 Q05204 denotes LAMP-1
T126 1819-1825 PR:000002060 denotes LAMP-1
T127 1819-1825 P11438 denotes LAMP-1
T128 1819-1825 PR:P05300 denotes LAMP-1
T129 1819-1825 P49129 denotes LAMP-1
T130 1819-1825 PR:Q7Y228 denotes LAMP-1
T131 1819-1825 PR:P11438 denotes LAMP-1
T132 1819-1825 P05300 denotes LAMP-1
T133 1819-1825 P14562 denotes LAMP-1
T134 1819-1825 PR:P11279 denotes LAMP-1
T135 1819-1825 P11279 denotes LAMP-1
T136 1849-1857 UBERON:0002435 denotes striatum
T137 1849-1857 UBERON:0005383 denotes striatum
T138 1862-1878 UBERON:0002038 denotes substantia nigra
T139 1936-1939 P47936 denotes CB2
T140 1936-1939 P34972 denotes CB2
T141 1936-1939 P24027 denotes CB2
T142 1936-1939 PR:000001126 denotes CB2
T143 1936-1939 Q9QZN9 denotes CB2
T144 1936-1948 D043885 denotes CB2 receptor
T145 1986-2001 D063388 denotes endocannabinoid
T146 1986-2001 CHEBI:67197 denotes endocannabinoid
T147 1986-2001 D063388 denotes endocannabinoid
T148 2002-2011 GO:0023052 denotes signaling
T149 2020-2033 UBERON:0002420 denotes basal ganglia
T152 2020-2033 UBERON:0006098 denotes basal ganglia
T153 2020-2033 UBERON:0010011 denotes basal ganglia
T150 2020-2033 D001480 denotes basal ganglia
T151 2020-2033 D001480 denotes basal ganglia
T155 2157-2162 PR:Q5S006 denotes LRRK2
T156 2157-2162 PR:000003033 denotes LRRK2
T157 2157-2162 PR:Q5S007 denotes LRRK2
T158 2163-2173 SO:0000781 denotes transgenic
T159 2163-2178 10090 denotes transgenic mice
T160 2163-2178 D008822 denotes transgenic mice
T161 2174-2178 PR:000005054 denotes mice
T163 2174-2178 O89094 denotes mice
T167 2221-2227 PR:P14562 denotes LAMP-1
T168 2221-2227 Q05204 denotes LAMP-1
T169 2221-2227 PR:000002060 denotes LAMP-1
T170 2221-2227 P11438 denotes LAMP-1
T171 2221-2227 PR:P05300 denotes LAMP-1
T172 2221-2227 P49129 denotes LAMP-1
T173 2221-2227 PR:Q7Y228 denotes LAMP-1
T174 2221-2227 PR:P11438 denotes LAMP-1
T175 2221-2227 P05300 denotes LAMP-1
T176 2221-2227 P14562 denotes LAMP-1
T177 2221-2227 PR:P11279 denotes LAMP-1
T178 2221-2227 P11279 denotes LAMP-1
T179 2251-2264 UBERON:0002420 denotes basal ganglia
T182 2251-2264 UBERON:0006098 denotes basal ganglia
T183 2251-2264 UBERON:0010011 denotes basal ganglia
T180 2251-2264 D001480 denotes basal ganglia
T181 2251-2264 D001480 denotes basal ganglia
T185 2301-2304 UBERON:0001017 denotes CNS
T186 2438-2441 P47936 denotes CB2
T187 2438-2441 P34972 denotes CB2
T188 2438-2441 P24027 denotes CB2
T189 2438-2441 PR:000001126 denotes CB2
T190 2438-2441 Q9QZN9 denotes CB2
T191 2438-2450 D043885 denotes CB2 receptor
T192 2492-2497 PR:Q5S006 denotes LRRK2
T193 2492-2497 PR:000003033 denotes LRRK2
T194 2492-2497 PR:Q5S007 denotes LRRK2
T195 2498-2508 SO:0000781 denotes transgenic
T196 2498-2513 10090 denotes transgenic mice
T197 2498-2513 D008822 denotes transgenic mice
T198 2509-2513 PR:000005054 denotes mice
T200 2509-2513 O89094 denotes mice
T202 2613-2626 UBERON:0002420 denotes basal ganglia
T205 2613-2626 UBERON:0006098 denotes basal ganglia
T206 2613-2626 UBERON:0010011 denotes basal ganglia
T203 2613-2626 D001480 denotes basal ganglia
T204 2613-2626 D001480 denotes basal ganglia
T208 2678-2682 PR:000005054 denotes mice
T210 2678-2682 O89094 denotes mice
T209 2678-2682 D051379 denotes mice
T211 2678-2682 10095 denotes mice

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 112-302 DRI_Background denotes Most of cases of Parkinson's disease (PD) have a sporadic origin, with their causes mostly unknown, although overexposure to some environmental factors has been found to occur in some cases.
T2 303-409 DRI_Background denotes Other forms of parkinsonism are the consequence of dominant or recessive mutations in specific genes, e.g.
T3 410-591 DRI_Background denotes α-synuclein, parkin and, more recently, leucine-rich repeat kinase 2 (LRRK2), whose G2019S mutation represents the most prevalent form of late-onset, autosomal dominant familial PD.
T4 592-792 DRI_Outcome denotes A transgenic mouse model expressing the G2019S mutation of LRRK2 is already available and apparently may represent a valuable experimental model for investigating PD pathogenesis and novel treatments.
T5 793-1221 DRI_Approach denotes We designed a long-term study with these animals aimed at: (i) elucidating the changes experienced by the endocannabinoid signaling system in the basal ganglia during the progression of the disease in these mice, paying emphasis in the CB2 receptor, which has emerged as a promising target in PD, and (ii) evaluating the potential of compounds selectively activating this CB2 receptor, as disease-modifying agents in these mice.
T6 1222-1593 DRI_Outcome denotes Our results unequivocally demonstrate that LRRK2 transgenic mice develop motor impairment consisting of small anomalies in rotarod performance (presumably reflecting a deficit in motor coordination and dystonia) and a strong deficiency in the hanging-wire test (reflecting muscle weakness), rather than hypokinesia which was difficult to be demonstrated in the actimeter.
T7 1594-1818 DRI_Background denotes These behavioral responses occurred in absence of any evidence of reactive gliosis and neuronal losses, as well as synaptic deterioration in the basal ganglia, except an apparent impairment in autophagy reflected by elevated
T8 1842-1879 DRI_Background denotes in the striatum and substantia nigra.
T9 1880-2179 DRI_Outcome denotes Furthermore, there were no changes in the status of the CB2 receptor, as well as in other elements of the endocannabinoid signaling, in the basal ganglia, but, paradoxically, the selective activation of this receptor partially reversed the deficits in the hanging-wire test of LRRK2 transgenic mice.
T10 2180-2220 DRI_Challenge denotes This was accompanied by normalization in
T11 2244-2388 DRI_Challenge denotes in the basal ganglia, although it is possible that other CNS structures, remaining to be identified, are involved in the behavioral improvement.
T12 2389-2683 DRI_Outcome denotes In summary, our data support the interest of the CB2 receptor as a potential pharmacological target in LRRK2 transgenic mice, although the neuronal substrates underlying these benefits might be not completely related to the basal ganglia and to the presumed parkinsonian features of these mice.